Drugs / CD19/BCMA-targeted CAR-T lentiviral vector drug
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07490951 | Mar 2026 → Dec 2029 expected | autoimmune disease | Shenzhen Genocury Biotech Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/BCMA-targeted CAR-T lentiviral vector drug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07490951 ↗ |
| Route | Intravenous | “administered intravenously” NCT07490951 ↗ |
| Target | CD19 | “The CD19/BCMA-targeted CAR-T lentiviral vector drug is administered intravenously, and autologous CD19/BCMA-targeted CAR-T cells are produced in the patient's body following infusion.” NCT07490951 ↗ |